Therapeutic Area: Oncology

Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

Berner F, et al.
Science Immunology
September 2022
immuneAccess
Authors and Affiliates
Fiamma Berner 1, David Bomze 1,2,3, Christa Lichtensteiger 1, Vincent Walter 4, Rebekka Niederer 1,5, Omar Hasan Ali 1,6,7, Nina Wyss 1,5, Jens Bauer 8,9,10, Lena Katharina Freudenmann 9,11, Ana Marcu 9, Eva-Maria Wolfschmitt 9, Sebastian Haen 9, Thorben Gross 9, Marie-Therese Abdou 1, Stefan Diem 12, Stella Knöpfli 1, Tobias Sinnberg 4,10, Kathrin Hofmeister 4, Hung-Wei Cheng 1, Marieta Toma 13, Niklas Klümper 14,15, Mette-Triin Purde 1, Oltin Tiberiu Pop 1, Ann-Kristin Jochum 1,16, Steve Pascolo 7, Markus Joerger 12, Martin Früh 12,17, Wolfram Jochum 16, Hans-Georg Rammensee 9,10,11, Heinz Läubli 18, Michael Hölzel 15, Jacques Neefjes 19, Juliane Walz 8,9,10,11,20, Lukas Flatz 1,4,5,7,12; 1 Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 4 Department of Dermatology, University Hospital Tübingen, University of Tübingen, Tübingen, Germany. 5 Department of Dermatology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 6 Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada. 7 Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 8 Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany. 9 Interfaculty Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. 10 Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany. 11 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany. 12 Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 13 Institute of Pathology, University Hospital Bonn (UKB), University of Bonn, Bonn, Germany. 14 Department of Urology, University Hospital Bonn (UKB), University of Bonn, Bonn, Germany. 15 Institute of Experimental Oncology, University Hospital Bonn (UKB), University of Bonn, Bonn, Germany. 16 Institute of Pathology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 17 Department of Oncology, University of Bern, Bern, Switzerland. 18 Division of Oncology, University Hospital Basel, University of Basel, Basel, Switzerland. 19 Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Netherlands. 20 Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Robert Bosch Center for Tumor Diseases (RBCT), Stuttgart, Germany.

Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients

Muraro E, et al.
Frontiers in Oncology
September 2022
immuneAccess
Authors and Affiliates
Elena Muraro 1, Fabio Del Ben 2, Matteo Turetta 1, Daniela Cesselli 2,3, Michela Bulfoni 3, Rita Zamarchi 4, Elisabetta Rossi 4,5, Simon Spazzapan 6, Riccardo Dolcetti 7,8,9,10, Agostino Steffan 1, Giulia Brisotto 1; 1 Immunopathology and Cancer Biomarkers Units, Department of Translational Research, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy. 2 Department of Medicine, University of Udine, Udine, Italy. 3 Institute of Pathology, University Hospital of Udine (Azienda sanitaria universitaria Friuli Centrale, ASUFC), Udine, Italy. 4 Department of Surgery, Oncology & Gastroenterology, University of Padova, Padua, Italy. 5 Veneto Institute of Oncology IOV - Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy. 6 Medical Oncology and Cancer Prevention Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy. 7 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 8 Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia. 9 Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, Australia. 10 The University of Queensland Diamantina Institute, Brisbane, QLD, Australia.

Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model

Kang J, et al.
Journal for ImmunoTherapy of Cancer
September 2022
Authors and Affiliates
Jinho Kang ,1 Hye-Jin Lee,1 Jimin Lee,1 Jinhwa Hong,1 Yeul Hong Kim,1 Mary L Disis,2 Jeong-An Gim,3 Kyong Hwa Park1; 1 Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea. 2 Department of Medicine, University of Washington, Seattle, Washington, USA. 3 Center for Research Support, Korea University College of Medicine, Seoul, South Korea. 4 Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea khpark@korea.ac.kr.

TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL

Kirsch IR, et al.
Science Translational Medicine
August 2022
Authors and Affiliates
Ilan R Kirsch #,1, Rei Watanabe #,2, John T O'Malley 2, David W Williamson 1, Laura-Louise Scott 2, Christopher P Elco 3, Jessica E Teague 2, Ahmed Gehad 2, Elizabeth L Lowry 2, Nicole R LeBoeuf 2,4, James G Krueger 5, Harlan S Robins 1, Thomas S Kupper 2,4, Rachael A Clark 2,4; 1 Adaptive Biotechnologies, Seattle, WA, USA. 2 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3 Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 4 Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. 5 Department of Dermatology, Rockefeller University, New York, NY, USA. # Contributed equally.

Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice

Jaini R, et al.
August 2022
Authors and Affiliates
Ritika Jaini 1,2,3, Matthew G Loya 1, Alexander T King 1, Stetson Thacker 1,2, Nicholas B Sarn 1,4, Qi Yu 1, George R Stark 5,2,4, Charis Eng 1,2,4,3; 1 Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. 2 Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. 3 Germline High Risk Focus Group, CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. 4 Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. 5 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Tyrosine kinase inhibition alters intratumoral CD8+ T-cell subtype composition and activity

Tieniber AD, et al.
Cancer Immunology Research
August 2022
Authors and Affiliates
Andrew D Tieniber 1, Andrew N Hanna 1, Benjamin D Medina 2, Gerardo A Vitiello 3, Mark S Etherington 4, Mengyuan Liu 5, Kevin J Do 6, Ferdinand Rossi 7, Ronald P DeMatteo 4; 1 University of Pennsylvania, Philadelphia, PA, United States. 2 Memorial Sloan Kettering Cancer Center, New York, United States. 3 Memorial Sloan Kettering Cancer Center, New York, NY, United States. 4 Hospital of the University of Pennsylvania, Philadelphia, PA, United States. 5 Weill Cornell Medicine, New York, NY, United States. 6 University of Pennsylvania, Philadelphia, Pennsylvania, United States. 7 Hospital of the University of Pennsylvania, Philadelphia, United States.

A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

Wu Y, et al.
Nature Cancer
August 2022
Authors and Affiliates
Yin Wu #1,2,3,4, Dhruva Biswas #1,2,5, Ieva Usaite 1, Mihaela Angelova 2, Stefan Boeing 6, Takahiro Karasaki 1,2, Selvaraju Veeriah 1, Justyna Czyzewska-Khan 1, Cienne Morton 3, Magdalene Joseph 3,4, Sonya Hessey 1,7, James Reading 1,8, Andrew Georgiou 1,8, Maise Al-Bakir 2, TRACERx Consortium, Nicholas McGranahan 1,9, Mariam Jamal-Hanjani 1,7, Allan Hackshaw 10, Sergio A. Quezada 1,8, Adrian C. Hayday 3,4, and Charles Swanton 1,2; 1 Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. 2 Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. 3 Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King’s College London, London, UK. 4 Immunosurveillance Laboratory, The Francis Crick Institute, London, UK. 5 Bill Lyons Informatics Centre, University College London Cancer Institute, London, UK. 6 Bioinformatics & Biostatistics and Software Development & Machine Learning Team, The Francis Crick Institute, London, UK. 7 Cancer Metastasis Lab, University College London Cancer Institute, London, UK. 8 Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. 9 Cancer Genome Evolution Research Group, University College London Cancer Institute, London, UK. 10 Cancer Research UK & University College London Cancer Trials Centre, University College London, London, UK. # These authors contributed equally

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma

Wang X, et al.
Journal for ImmunoTherapy of Cancer
August 2022
Authors and Affiliates
Xuefeng Wang 1, Jameel Muzaffar 2, Kedar Kirtane 2, Feifei Song 2, Matthew Johnson 2, Michael J Schell 1, Jiannong Li 1, Sean J Yoder 3, Jose R Conejo-Garcia 4, Jose A Guevara-Patino 4, Marcelo Bonomi 5, Priyanka Bhateja 5, James W Rocco 6, Conor E Steuer 7, Nabil F Saba 7, Christine H Chung 8; 1 Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA. 2 Department of Head and Neck-Endocrine Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA. 3 Department of Molecular Genomics Core, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA. 4 Department of Immunology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA. 5 Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 6 Department of Otolaryngology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 7 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. 8 Department of Head and Neck-Endocrine Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA Christine.chung@moffitt.org.

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Jing R, et al.
Cell Stem Cell
August 2022
Authors and Affiliates
Ran Jing 1, Irene Scarfo 2, Mohamad Ali Najia 3, Edroaldo Lummertz da Rocha 4, Areum Han 1, Michael Sanborn 5, Trevor Bingham 5, Caroline Kubaczka 1, Deepak K Jha 1, Marcelo Falchetti 6, Thorsten M Schlaeger 7, Trista E North 8, Marcela V Maus 2, George Q Daley 9; 1 Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. 2 Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02114, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. 3 Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard-MIT Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. 4 Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis, SC 88040-900, Brazil. 5 Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA. 6 Graduate Program of Pharmacology, Center for Biological Sciences, Federal University of Santa Catarina, Florianópolis, SC 88040-900, Brazil. 7 Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA. 8 Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA; Developmental and Regenerative Biology Program, Harvard Medical School, Boston, MA 02115, USA. 9 Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA; Developmental and Regenerative Biology Program, Harvard Medical School, Boston, MA 02115, USA. Electronic address: george.daley@childrens.harvard.edu.

Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses

Lyudovyk O, et al.
Cancer Cell
August 2022
Authors and Affiliates
Olga Lyudovyk 1, Justin Y Kim 2, David Qualls 3, Madeline A Hwee 4, Ya-Hui Lin 4, Sawsan R Boutemine 5, Yuval Elhanati 1, Alexander Solovyov 1, Melanie Douglas 3, Eunise Chen 6, N Esther Babady 7, Lakshmi Ramanathan 8, Pallavi Vedantam 9, Chaitanya Bandlamudi 9, Sigrid Gouma 10, Philip Wong 9, Scott E Hensley 11, Benjamin Greenbaum 12, Alexander C Huang 13, Santosha A Vardhana 14; 1 Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2 Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. 3 Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6 University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA. 7 Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. 11 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. 12 Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Physiology, Biophysics & Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: greenbab@mskcc.org. 13 Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: alexander.huang@pennmedicine.upenn.edu. 14 Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: vardhans@mskcc.org.